A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
A Phase III Clinical Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
Ganzhou Hemay Pharmaceutical Co., Ltd
162 participants
Nov 13, 2023
INTERVENTIONAL
Conditions
Summary
This is a phase 3, multi-center, randomized, placebo-controlled, double-blind, parallel-group study with an equal randomization among the Hemay005 high dose, lower dose and placebo treatment groups. After subject randomization, each subject will enter an core-treatment Phase for 12 weeks following an extended-treatment phase for another 40 weeks and a follow up phase for 4weeks.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Hemay005 tables 60mg bid p.o;
Hemay005 tables 45mg bid p.o;
placebo to Hemay005 tables bid p.o
Locations(22)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06145893